Taisho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taisho Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug TS-172 tested in patients with liver impairment Results expected Oct 2026 (estimated)
- New pill aims to tame dangerous phosphate levels in dialysis patients Results expected Nov 2026 (estimated)
- New hope for dialysis patients: drug targets dangerous phosphorus levels Results expected Dec 2026 (estimated)
- New pill aims to tame phosphorus in kidney dialysis patients Results expected May 2027 (estimated)
- New pill aims to tame dangerous phosphate in kidney patients Results expected Jul 2027 (estimated)
-
New pill helps dialysis patients control dangerous phosphorus levels
Disease control CompletedThis study tested a new medicine called TS-172 in 101 adults on hemodialysis who had high phosphorus levels. The goal was to see if the drug could help more patients reach a safe phosphorus level in their blood. Results showed that TS-172 was better than a placebo at controlling …
Phase 3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Meal timing tested for new drug TS-172 in healthy volunteers
Knowledge-focused CompletedThis early study tested a drug called TS-172 in 16 healthy Japanese men to see if taking it before or after a meal changes how the body handles phosphorus and sodium. The trial is complete and focused on safety and basic effects, not on treating any disease. It provides initial d…
Phase 1 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC